Optic Nerve Neuroprotection in Glaucoma: A Narrative Review.
Angela D'AngeloLivio VitielloFilippo LixiGiulia AbbinanteAlessia CoppolaVincenzo GagliardiAlfonso PellegrinoGiuseppe GiannaccarePublished in: Journal of clinical medicine (2024)
In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology's molecular cause is still mostly unknown, and the current treatments are not able to alter the disease's natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds' pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits.
Keyphrases
- optic nerve
- cerebral ischemia
- subarachnoid hemorrhage
- optical coherence tomography
- brain injury
- blood brain barrier
- end stage renal disease
- clinical practice
- primary care
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- oxidative stress
- electronic health record
- spinal cord injury
- white matter
- big data
- resting state
- smoking cessation
- data analysis